SBC Medical Group Holdings Incorporated Q3 2026 Earnings Call Summary Moby Intelligence Fri, November 13, 2026 at 5:08 PM EST 4 min read NVDA -2.76% SBC +35.39% 4937.T -8.44% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management attributes the 66% growth in operating income to the inherent operating leverage of the MSO model, where profit grew twice as fast as revenue by increasing clinic productivity and fees without proportional headcount increases.
Revenue growth was driven by a combination of service fee revisions implemented in August, increased rental revenue from new medical equipment, and the consolidation of the Waqoo segment.
Same-clinic revenue growth of 7% is being fueled by a dual increase in customer visits (up 9%) and average spend per visit (up 4%), indicating a strengthening of the existing clinic base alongside network expansion.
The company is pivoting toward a longevity framework, leveraging its existing infrastructure of 293 clinics to provide a full cycle of diagnosis, personalized treatment, and verification.
SBC is developing a local Large Language Model (LLM) to secure patient data and decouple inference costs from cloud API pricing, aiming to improve economics while providing proprietary clinical insights.
Management believes their extensive physical medical infrastructure creates a difficult-to-replicate moat in the emerging longevity market compared to competitors who only offer diagnostics without intervention capabilities.
The company expects meaningful revenue contribution from longevity services by 2028, with blood biomarker and DNA methylation testing initiatives beginning in late 2026.
Management plans to maintain the current pace of aesthetic clinic expansion in 2027 while aggressively growing non-aesthetic services like dentistry and orthopedics through both organic growth and M&A.
Strategic expansion into the U.S. involves a dual approach: supporting OrangeTwist's growth (targeting 8-10 new clinics in 3-4 months) and launching SBC-branded clinics within 6-12 months.
Management anticipates further margin expansion driven by AI-enabled productivity gains, such as automatic charting and optimized shift scheduling, alongside increased platform efficiency as the network grows.
Capital priorities are focused on M&A and de novo clinic openings to drive growth, with no plans for share buybacks as the focus remains on improving liquidity and free float.
Management is actively selecting independent directors to address investor concerns regarding the current board structure, where the CEO holds approximately 80% of shares.
Recent structural reforms and strategic pricing adjustments have led to a favorable competitive environment, as some smaller competitors have been forced to exit the market due to an inability to match SBC's pricing trends.
The consolidation of the Waqoo segment contributed $5.6 million to revenue this quarter and provides the technological base for the company's new DNA methylation testing initiatives.
Management expressed confidence in long-term sustainability due to multiple growth engines including fee revisions, equipment rentals, and clinic expansion.
Profitability is expected to improve further as AI activities, such as automated charting and scheduling, begin to yield operational results in the near future.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
The U.S. strategy involves partnering with OrangeTwist for med spas while researching market-specific SBC brand offerings for a 6-12 month launch window.
Management is taking a cautious approach by finding established platforms to support before taking larger stakes as they become more familiar with the U.S. market.
Growth is attributed to strategic pricing adjustments over the last two years and the introduction of state-of-the-art equipment to attract high-literacy aesthetic patients.
The expansion of specialized networks, such as the NEO Skin Clinic with advanced laser equipment, has successfully increased average spend per visit.
Meaningful revenue is expected by 2028 as the longevity trend in Japan matures toward levels seen in the U.S.
Management emphasizes that their 293-clinic network is a decisive strength that competitors cannot easily replicate in the intervention phase of the longevity cycle.
Despite a low valuation, management is prioritizing M&A and new clinics over buybacks to improve liquidity and free float.
Daily trading volume has already increased 4.1x since July, and management expects this trend to continue as the shareholder base expands.
